Form 8-K - Current report:
SEC Accession No. 0000950170-23-039867
Filing Date
2023-08-08
Accepted
2023-08-08 16:24:43
Documents
14
Period of Report
2023-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tern-20230808.htm   iXBRL 8-K 58005
2 EX-99.1 tern-ex99_1.htm EX-99.1 179884
3 GRAPHIC img52906712_0.jpg GRAPHIC 6619
  Complete submission text file 0000950170-23-039867.txt   383357

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tern-20230808_lab.xml EX-101.LAB 14572
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tern-20230808.xsd EX-101.SCH 2478
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tern-20230808_pre.xml EX-101.PRE 10683
8 EXTRACTED XBRL INSTANCE DOCUMENT tern-20230808_htm.xml XML 5119
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39926 | Film No.: 231151780
SIC: 2834 Pharmaceutical Preparations